Fully robotic pancreatoduodenectomy. First procedure in Mexico

Pancreatoduodenectomía totalmente robótica. Primer procedimiento en México

Ductal adenocarcinoma of the pancreas is the most common biliopancreatic tumor. It accounts for 90% of those lesions and has a survival rate of 8.3%. According to the National Cancer Institute, the pathology makes up approximately 3% of all cancers in the United States and 7% of cancer deaths. Cholangiocarcinomas constitute 3% of gastrointestinal tumors, and tumors of the ampulla of Vater, called ampullomas, make up 2% of all digestive tract tumors and can arise from any of the 3 types of epithelium that form the papilla.

Pancreatoduodenectomy was described by Alessandro Codivilla in 1898. In 1909, Kausch successfully performed the first regional resection of a periampullary tumor and the procedure was later popularized by Allen O. Whipple (1935). It is considered one of the most complex operations of the digestive tract due to the combined challenge of careful dissection in close proximity to critical vascular structures and the restoration of the enteric continuity through the construction of 3 anastomoses (pancreatojejunostomy, hepaticojejunostomy, and gastrojejunostomy). The da Vinci surgical system is composed of a robot with 3 or 4 arms operated by a surgeon from a console. Robotic-assisted surgery overcomes many of the main deficiencies of traditional laparoscopy, which include monocular vision, limited degrees of freedom, and the effects of pivot and fulcrum. In contrast, the robotic platform provides the surgeon with three-dimensional stereoscopic vision of the operating field. It restores hand-eye coordination, eliminating hand tremor, and the instrumentation favors complex angles of attack. Thus, the surgeon’s skills are enhanced, especially those involved in highly complex suturing.

The first robotic-assisted pancreatoduodenectomy was reported on in 2003 by Giulianotti et al. They performed the first 6 pancreatoduodenectomies utilizing a hybrid technique: laparoscopic resection and robotic-assisted reconstruction. The resection and reconstruction in the last 2 procedures were completely carried out through robotic assistance. Mean surgery duration was 490 min and the morbidity and mortality rates were 37.5% and 12.5%, respectively.

The development of minimal invasion in pancreatoduodenectomy in Mexico has advanced relatively slowly. At our hospital, the first laparoscopic pancreatoduodenectomy was performed by the physicians Carlos Morales, José Luis Beristain, and Adolfo Cuendis, on March 7, 2013. Enthusiasm for the approach was then demonstrated by numerous surgical groups and in October 2015 the da Vinci Robotic System was introduced at our hospital. Complex hepatopancreatobiliary surgery immediately benefited from that approach, with the first hybrid pancreatoduodenectomy performed on April 28, 2016, with laparoscopic resection and robotic-assisted reconstruction.

We present herein the first case of fully robotic pancreatoduodenectomy performed at the Hospital General “Dr. Manuel Gea González”.

A 66-year-old man had a history of 8-year progression of controlled diabetes mellitus. His current illness began one year prior to diagnosis, with acholia, choluria, jaundice of the skin and teguments, 20kg weight loss, and pain in the right hypochondrium. He presented with symptoms of cholangitis, prior to his referral to our service, that required management with endoscopic retrograde cholangiopancreatography (ERCP) and endostent as peripancreatic tumor palliation. The initial post-ERCP laboratory tests showed obstructive jaundice with total bilirubin of 22mg/dl, mainly dependent on direct bilirubin levels, no leukocytosis, and a CA 19-9 level of 116U.

As part of the preoperative protocol, endoscopic ultrasound was carried out, diagnosing a tumor of the ampulla of Vater. The uT2 lesion biopsy was positive for adenocarcinoma of the ampulla (Fig. 1A1-A4). Ultrasound of the liver and biliary tract was ordered, identifying an enlarged gallbladder (Fig. 1B1-B2). A contrast-enhanced abdominal computed tomography scan revealed a peripancreatic tumor with associated bile duct and pancreatic duct dilatation up to 8mm, with no signs of vascular invasion or distant disease (Fig. 1C1-C2).

After being approved by the multidisciplinary committee of the hospital, a fully robotic pylorus-preserving pancreatoduodenectomy was performed, with an operative time of 8h, utilizing 4 robotic arms, with the patient in the French position (Fig. 1D1-D2). Surgery duration was longer than that reported with a standardized curve in the literature, precisely because it was the first procedure of that type performed by our group. However, our operative time with that approach was similar to the ones reported by Giulianotti in 2003. As reported in large case series, surgery duration will progressively decrease as more such procedures are performed. Resection took up most of the time of the procedure, with a duration of 4h 45min, and 3h 15min for reconstruction. Operative time for open surgery at teaching and training centers, such as ours, is around 5h. However, minimally invasive approaches provide a shorter recovery period, less pain, fewer hernias, and lower infection rates. A 2-layer duct-to-mucosa pancreatojejunostomy with no stenting, a single-layer side-to-side hepaticojejunostomy, and a 2-layer end-to-side duodenojejunostomy were performed, achieving RO with intraoperative blood loss of 400cc.

Postoperative recovery was favorable, with no development of complications, and the patient was discharged from the hospital on the 9th day after surgery. We are aware that the time of release in the literature is on average 3 days shorter, but because it was our first case, initiation and tolerance of oral intake took longer than usual.

The pathology report indicated moderately differentiated adenocarcinoma (grade II) of the ampulla of Vater, invading the pancreas and duodenal wall, with metastasis to the peripancreatic lymph nodes. The tumor measured...

---

5 × 3.5 cm, the surgical margins were disease-free, and it was staged as T3 N1 M0, with a lymph node harvest of 25 nodes. The patient was referred for multimodal treatment in good condition (Fig. 1E). Upon his release, the patient was referred for follow-up and multimodal treatment, receiving adjuvant therapy. However, he presented with disease recurrence and progression at month 14 of follow-up.

To the best of our knowledge, the present case of fully robotic pancreatoduodenectomy performed by the multidisciplinary group of our hospital center is the first to be reported in Mexico. We are aware that the management of hepatobiliary malignant disease requires highly specialized personnel at high-volume centers. In that respect, we are a team that is made up of surgeons trained in minimally invasive hepatopancreatobiliary surgery, oncology surgeons trained in minimally invasive surgery, and oncology surgeons with formal training in hepatopancreatobiliary surgery. As a whole, our group performs more than 40 surgeries per year.

**Ethical disclosures**

Before performing the surgical procedure, a written statement of informed consent was requested of the patient and his responsible relative, observed by 2 witnesses. Before the surgical procedure, the case was presented to the multidisciplinary committee of the Hospital General Dr. Manuel Gea González, which evaluated its risks and benefits. However, because it was a case report and not a research study, as such, authorization by an Ethics Committee was not requested.

The authors declare that the present article contains no personal information of any type that could identify the patient.

**Financial disclosure**

No financial support was received in relation to this article.

**Conflict of interest**

The authors declare that there is no conflict of interest.

**Acknowledgements**

The authors wish to thank the Hospital General Dr. Manuel Gea González for the opportunity to work with this technology and all the members of the team that worked together, seeking the wellbeing of the patient.

**References**

Gastric schwannoma: A rarity among mesenchymal tumors of the gastrointestinal tract

Schwannoma gástrico: una rareza entre los tumores mesenquimatosos del tracto gastrointestinal

A previously healthy 55-year-old woman sought medical attention at our department complaining of epigastric pain of 6-month progression, accompanied by heartburn and early satiety. She had been taking over-the-counter proton pump inhibitors and prokinetics, with no clinical improvement. We scheduled her for an abdominal computed tomography scan and upper endoscopy. However, before her appointment, she presented with an episode of melena and went to the emergency department, at which time the abovementioned studies were then carried out. Endoscopy revealed a submucosal growth over the anterior portion of the gastric fundus, with no signs of active bleeding. Following stabilization, a computed tomography scan of the abdomen and pelvis was ordered, identifying an exophytic, well-defined (4.4 × 5.2 cm) tumor over the gastric fundus, with no signs of locally advanced or metastatic disease (Fig. 1A and B). An endoscopic ultrasound study confirmed lesion invasion through the muscularis propria, precluding the safe performance of endoscopic resection. The patient was then scheduled for surgery the following day.

During the surgical procedure, a supraumbilical midline incision was made, followed by an extensive wedge resection of the stomach that enabled complete tumor extraction (Fig. 1D and E). A 7 × 5 cm specimen was obtained, and no peritoneal implants, adenopathies, or metastases were found. The histopathologic analysis reported a gastric schwannoma (GS) with negative margins and a mitotic index of 1/50 high power fields (Fig. 2). The patient was discharged after an uneventful postoperative period and has been followed at our outpatient clinic. At present, she shows no signs of recurrence or morbidity.

GSs are benign, mesenchymal, slow-growing tumors that originate from Schwann cells. They account for 6.3% of all gastric mesenchymal tumors and 4% of all benign gastric tumors. When schwannomas are found in the gastrointestinal tract, they usually arise from the nerve sheath of Auerbach’s plexus. Female predominance has been described in the literature, with a male:female ratio of 1:3 and an average age at diagnosis of 57 years. Patients with GS are usually asymptomatic, and the tumor is an incidental finding in 43.3% of cases. Symptomatic patients typically present with abdominal pain, followed by upper gastrointestinal bleeding. Less frequently, they present with a palpable abdominal tumor (3%), anorexia (3%), dyspepsia (1.8%), weight loss (1.2%), and vomiting (0.6%).

Preoperative work-up can be misleading in patients with GS. Computed tomography usually reveals a well-circumscribed lesion, but radiologic findings are not very specific and are often suggestive of a gastrointestinal stromal tumor. Upper gastrointestinal endoscopy shows GSs as solid submucosal sessile tumors that frequently have an ulcerated mucosa, whereas endoscopic ultrasound identifies a hypoechoic lesion arising from the fourth echo layer of the stomach. Endoscopic ultrasound enables the performance of fine needle aspiration biopsy during the procedure, which is diagnostic in up to 85.2% of cases. Histopathologic analysis is the current gold standard of diagnosis. Schwann cells are characteristically arranged in a fascicular manner and display positive immunohistochemistry for protein S-100, vimentin, and glial fibrillary acidic protein, confirming the diagnosis. Surgical resection is the only curative treatment for GS, and the specific type of procedure will depend on the size and location of the lesion. Endoscopic resection is not feasible in most cases, because the neoplasia usually arises from Auerbach’s plexus, and growths tend to involve the entire width of the muscularis propria. On the other hand, minimally invasive (laparoscopic) techniques have shown satisfactory results. Formal lymph node resection is not necessary, as GSs seldom have lymphatic dissemination or malignant transformation. Only a few such cases have been reported in the medical literature.

Please cite this article as: Sánchez-Morales GE, et al. Schwannoma gástrico: una rareza entre los tumores mesenquimatosos del tracto gastrointestinal. Revista de Gastroenterología de México. 2020;85:102–104.